Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

AbbVie Inc.

Close the acquisition of ImmunoGen, Inc

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
2 Feb 2024
Due
30 Jun 2024
Delivered
12 Feb 2024
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“which are anticipated to close in the middle of 2024”
  • SourceAbbVie Inc. Form 8-K press release, 2024-02-02
  • FilingSEC filing index
  • Deadline as statedin the middle of 2024
  • Deadline used30 Jun 2024, the last day of the stated period
  • TypeTransaction
  • Permanent referenceKI-C-2024-ABBV-005769
    Cite as https://keptindex.org/c/KI-C-2024-ABBV-005769/ — this address never changes.

What we found

Evidence strength A What the grades mean

AbbVie completed the ImmunoGen acquisition on February 12, 2024, before the mid-2024 deadline, as stated in later 10-Q and 10-K filings.

  • A
    AbbVie Inc. 10-Q filed 2024-11-04 Regulatory filing · published 4 Nov 2024 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint 186e355100a0
    “On February 12, 2024, AbbVie completed its previously announced acquisition of ImmunoGen.” ✓ confirmed on the page
  • A
    AbbVie Inc. 10-K filed 2025-02-14 Regulatory filing · published 14 Feb 2025 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint 547649727de2
    “On February 12, 2024, AbbVie completed the acquisition of ImmunoGen, Inc. (ImmunoGen).” ✓ confirmed on the page

Market reaction: the shares moved -4.7% against the S&P 500 over the three sessions around the disclosure (1 Nov 2024 to 6 Nov 2024). What this measures

Checked 10 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Acquisition close
Indicative materiality
High rules
Action
Close
Deliverable
ImmunoGen acquisition
Language
Expected (“expects”, “plans”)
In the company’s control
Medium
Specificity
Medium

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you AbbVie Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2024-ABBV-005769 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.